Results 21 to 30 of about 5,954,250 (317)
Drug-induced mutations realise an evolutionary collateral cost of therapy.
, 2021 A Before therapy the target cell population (blue circle) is well-adapted to its microenvironment. B Initiation of control (drug therapy) drastically changes the growth conditions of the target population pushing it below zero level of growth (light blue
Teemu Kuosmanen (11473623) +5 more
core +1 more source
Puerarin Alleviates Vascular Cognitive Impairment in Vascular Dementia Rats
Frontiers in Behavioral Neuroscience, 2021 Cerebral ischemia triggers vascular dementia (VD), which is characterized by memory loss, cognitive deficits, and vascular injury in the brain. Puerarin (Pur) represents the major isoflavone glycoside of Radix Puerariae, with verified neuroprotective ...
Tiantian Zhu +32 more
doaj +1 more source
Comparative analysis of CDR3 length-dependent patterns in VHHs
Frontiers in ImmunologyIntroductionVHHs, or nanobodies, are distinguished by their compact size, high stability, and unique ability to selectively target specific epitopes. The CDR3 region in VHHs, which plays a crucial role in antigen binding, exhibits significant diversity ...
Lu Zhang +7 more
doaj +1 more source
Mycobacteriophages in diagnosis and alternative treatment of mycobacterial infections
Frontiers in Microbiology, 2023 Antimicrobial resistance is an increasing threat to human populations. The emergence of multidrug-resistant “superbugs” in mycobacterial infections has further complicated the processes of curing patients, thereby resulting in high morbidity and ...
Xudong Ouyang +14 more
doaj +1 more source
Drug resistance with monitored adherence [PDF]
, 2013 Drug resistance can be defined as the failure of a drug to exert its expected effect on pharmacological biomarkers and is caused by pharmacogenetic, cellular or clinical factors.
Walter, Philipp Niklaus
core +1 more source
Overcoming the challenges of drug resistance through combination drug delivery approach
, 2022 Anticancer and antimicrobial drug resistances are the most important problems that decrease the overall success of drug treatment in the clinic. The combination of two or more different kinds of drugs in clinical practice has been generally accepted as a
Tonbul, Hayrettin +6 more
core +1 more source
BMJ OpenObjective Nintedanib is approved for the treatment of interstitial lung disease (ILD) with progressive pulmonary fibrosis (PPF). Real-life data on nintedanib treatment for this indication and on the combined use of antifibrotic and immunomodulatory drugs
Mari Ainola +5 more
doaj +1 more source
miRNA-Based Technologies in Cancer Therapy
, 2023 The discovery of therapeutic miRNAs is one of the most exciting challenges for pharmaceutical companies. Since the first miRNA was discovered in 1993, our knowledge of miRNA biology has grown considerably.
Ioannis Michalopoulos +6 more
core +1 more source
Update on Viral Gene Therapy Clinical Trials for Retinal Diseases [PDF]
, 2022 In 2001, the first large animal was successfully treated with a gene therapy that restored its vision. Lancelot, the Briard dog that was treated, suffered from a human childhood blindness called Leber's congenital amaurosis type 2.
Cheng, Shun-Yun, Punzo, Claudio
core +1 more source
Communications BiologyObesity-induced changes in adipose vasculature are well documented, but systematic analyses in other tissues have not been as extensive. Here, we analyze the vessel-covered area and endothelial cell (EC) numbers in seven non-adipose organs (liver, heart,
Emmi Pakarinen +5 more
doaj +1 more source